The data will be presented at the American Academy of
Dermatology (AAD) 2025 Annual Meeting, which takes place
March 7-11, 2025, highlighting
HT-001 as a potential breakthrough therapy for EGFR
inhibitor-induced dermatologic toxicities.
The recent case study will be highlighted that demonstrated the
efficacy of HT-001 2% cream in a 59-year-old patient with
metastatic breast cancer undergoing treatment with paclitaxel,
trastuzumab, and pertuzumab. The patient developed pruritic,
burning red papules on the face, scalp, and upper back, a known
dermatologic side effect of EGFR inhibitors. After just one week of
applying HT-001 2% cream twice daily, the patient
experienced full symptom and lesion resolution, with no recurrence
of lesions in the following three weeks.
NEW
YORK, March 5, 2025 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused
biopharmaceutical company, is excited to announce promising
findings for its novel therapeutic candidate, HT-001, a
topical neurokinin 1 receptor (NK1R) antagonist, in the treatment
of Epidermal Growth Factor Receptor Inhibitor-Associated
Papulopustular Eruptions (EGFRi PPEs).
The data will be presented at the American Academy of
Dermatology (AAD) 2025 Annual Meeting, which takes place
March 7-11, 2025, highlighting
HT-001 as a potential breakthrough therapy for EGFR
inhibitor-induced dermatologic toxicities.
A recent case study demonstrated the efficacy of HT-001 2%
cream in a 59-year-old patient with metastatic breast cancer
undergoing treatment with paclitaxel, trastuzumab, and pertuzumab.
The patient developed pruritic, burning red papules on the face,
scalp, and upper back, a known dermatologic side effect of EGFR
inhibitors. After just one week of applying HT-001 2% cream
twice daily, the patient experienced full symptom and lesion
resolution, with no recurrence of lesions in the following three
weeks.
"These findings demonstrate the potential of HT-001 as a
safe and effective therapy for EGFR inhibitor-associated skin
toxicities," said Robb Knie, CEO at
Hoth Therapeutics. "With a significant unmet need for long-term,
well-tolerated treatment options, HT-001 could offer relief
to cancer patients experiencing debilitating skin reactions."
HT-001 works by blocking the pro-inflammatory effects of the
Substance P (SP)-NK1R pathway, a key mediator of neurogenic
inflammation. Preclinical research has shown that HT-001
reduces inflammation and hair loss associated with EGFR inhibitor
therapy. These latest clinical observations further support its
potential role in dermatologic oncology.
Hoth Therapeutics is currently conducting a Phase 2A clinical
trial to evaluate the efficacy and safety of HT-001 in a
broader patient population. The trial will assess the treatment's
effectiveness across varying severities of EGFRi PPEs and
explore its impact on other dermatologic manifestations induced by
EGFR inhibitors.
For more information about HT-001 and ongoing clinical
trials, visit www.hoththerapeutics.com
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative, impactful, and
ground-breaking treatments with a goal to improve patient quality
of life. We are a catalyst in early-stage pharmaceutical research
and development, elevating drugs from the bench to pre-clinical and
clinical testing. Utilizing a patient-centric approach, we
collaborate and partner with a team of scientists, clinicians, and
key opinion leaders to seek out and investigate therapeutics that
hold immense potential to create breakthroughs and diversify
treatment options. To learn more, please visit
https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based
upon Hoth's current expectations, which may
constitute forward-looking statements for the purposes of the safe
harbor provisions under the Private Securities Litigation Reform
Act of 1995 and other federal securities laws, and are subject to
substantial risks, uncertainties, and assumptions. These statements
concern Hoth's business strategies; the timing of regulatory
submissions; the ability to obtain and maintain regulatory approval
of existing product candidates and any other product candidates we
may develop, and the labeling under any approval we may obtain; the
timing and costs of clinical trials, and the timing and costs of
other expenses; market acceptance of our products; the ultimate
impact of the current coronavirus pandemic, or any other health
epidemic, on our business, our clinical trials, our research
programs, healthcare systems, or the global economy as a whole; our
intellectual property; our reliance on third-party organizations;
our competitive position; our industry environment; our anticipated
financial and operating results, including anticipated sources of
revenues; our assumptions regarding the size of the available
market, benefits of our products, product pricing, and timing of
product launches; management's expectation with respect to future
acquisitions; statements regarding our goals, intentions, plans,
and expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors"
in Hoth's most recent Annual Report on Form 10-K and Hoth's
other filings made with the U. S. Securities and Exchange
Commission. All such statements speak only as of the date made.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates, and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance,
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors
LLC Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-results-for-ht-001-in-treating-egfr-inhibitor-associated-papulopustular-eruptions-findings-to-be-presented-at-the-american-academy-of-dermatology-2025-annual-meeting-302393579.html
SOURCE Hoth Therapeutics, Inc.
